The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Pidomod (CAS 121808-62-6), also known as primo, spectrum leyi, is an immunomodulator, suitable for patients with low immune function of the body, and can be used to prevent acute infection, shorten the course of disease, reduce the severity of the disease, can be used as an auxiliary drug during the acute infection period.Mainly used in children recurrent respiratory tract infection, urinary tract infection (urinary tract infection), chronic bronchitis also has therapeutic effect, to the virus.Influenza and viral herpes are effective.It can also be used for infection caused by pneumococcal pneumonia and escherichia coli, pseudomonas aeruginosa and proteus.
The global Pidotimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pidotimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pidotimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pidotimod include Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical and Dr. Reddy’s, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pidotimod, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pidotimod.
Report Scope
The Pidotimod market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pidotimod market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pidotimod manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Peptide Company
Reco Tech
Manus Aktteva Biopharma
Joyochem
Changzhou Yinsheng Pharmaceutical
Dr. Reddy’s
Segment by Type
Piece
Oral Liquid
Capsule
Particles
Other
Segment by Application
Gynecological Infection
Urinary Tract Infection (UTI)
Respiratory Infections
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pidotimod manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pidotimod in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Pidomod (CAS 121808-62-6), also known as primo, spectrum leyi, is an immunomodulator, suitable for patients with low immune function of the body, and can be used to prevent acute infection, shorten the course of disease, reduce the severity of the disease, can be used as an auxiliary drug during the acute infection period.Mainly used in children recurrent respiratory tract infection, urinary tract infection (urinary tract infection), chronic bronchitis also has therapeutic effect, to the virus.Influenza and viral herpes are effective.It can also be used for infection caused by pneumococcal pneumonia and escherichia coli, pseudomonas aeruginosa and proteus.
The global Pidotimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pidotimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pidotimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pidotimod include Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical and Dr. Reddy’s, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pidotimod, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pidotimod.
Report Scope
The Pidotimod market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pidotimod market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pidotimod manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Peptide Company
Reco Tech
Manus Aktteva Biopharma
Joyochem
Changzhou Yinsheng Pharmaceutical
Dr. Reddy’s
Segment by Type
Piece
Oral Liquid
Capsule
Particles
Other
Segment by Application
Gynecological Infection
Urinary Tract Infection (UTI)
Respiratory Infections
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pidotimod manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pidotimod in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pidotimod Market Overview
1.1 Product Overview and Scope of Pidotimod
1.2 Pidotimod Segment by Type
1.2.1 Global Pidotimod Market Value Comparison by Type (2024-2030)
1.2.2 Piece
1.2.3 Oral Liquid
1.2.4 Capsule
1.2.5 Particles
1.2.6 Other
1.3 Pidotimod Segment by Application
1.3.1 Global Pidotimod Market Value by Application: (2024-2030)
1.3.2 Gynecological Infection
1.3.3 Urinary Tract Infection (UTI)
1.3.4 Respiratory Infections
1.3.5 Other
1.4 Global Pidotimod Market Size Estimates and Forecasts
1.4.1 Global Pidotimod Revenue 2019-2030
1.4.2 Global Pidotimod Sales 2019-2030
1.4.3 Global Pidotimod Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pidotimod Market Competition by Manufacturers
2.1 Global Pidotimod Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pidotimod Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pidotimod Average Price by Manufacturers (2019-2024)
2.4 Global Pidotimod Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pidotimod, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pidotimod, Product Type & Application
2.7 Pidotimod Market Competitive Situation and Trends
2.7.1 Pidotimod Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pidotimod Players Market Share by Revenue
2.7.3 Global Pidotimod Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pidotimod Retrospective Market Scenario by Region
3.1 Global Pidotimod Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pidotimod Global Pidotimod Sales by Region: 2019-2030
3.2.1 Global Pidotimod Sales by Region: 2019-2024
3.2.2 Global Pidotimod Sales by Region: 2025-2030
3.3 Global Pidotimod Global Pidotimod Revenue by Region: 2019-2030
3.3.1 Global Pidotimod Revenue by Region: 2019-2024
3.3.2 Global Pidotimod Revenue by Region: 2025-2030
3.4 North America Pidotimod Market Facts & Figures by Country
3.4.1 North America Pidotimod Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pidotimod Sales by Country (2019-2030)
3.4.3 North America Pidotimod Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pidotimod Market Facts & Figures by Country
3.5.1 Europe Pidotimod Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pidotimod Sales by Country (2019-2030)
3.5.3 Europe Pidotimod Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pidotimod Market Facts & Figures by Country
3.6.1 Asia Pacific Pidotimod Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pidotimod Sales by Country (2019-2030)
3.6.3 Asia Pacific Pidotimod Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pidotimod Market Facts & Figures by Country
3.7.1 Latin America Pidotimod Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pidotimod Sales by Country (2019-2030)
3.7.3 Latin America Pidotimod Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pidotimod Market Facts & Figures by Country
3.8.1 Middle East and Africa Pidotimod Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pidotimod Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pidotimod Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pidotimod Sales by Type (2019-2030)
4.1.1 Global Pidotimod Sales by Type (2019-2024)
4.1.2 Global Pidotimod Sales by Type (2025-2030)
4.1.3 Global Pidotimod Sales Market Share by Type (2019-2030)
4.2 Global Pidotimod Revenue by Type (2019-2030)
4.2.1 Global Pidotimod Revenue by Type (2019-2024)
4.2.2 Global Pidotimod Revenue by Type (2025-2030)
4.2.3 Global Pidotimod Revenue Market Share by Type (2019-2030)
4.3 Global Pidotimod Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pidotimod Sales by Application (2019-2030)
5.1.1 Global Pidotimod Sales by Application (2019-2024)
5.1.2 Global Pidotimod Sales by Application (2025-2030)
5.1.3 Global Pidotimod Sales Market Share by Application (2019-2030)
5.2 Global Pidotimod Revenue by Application (2019-2030)
5.2.1 Global Pidotimod Revenue by Application (2019-2024)
5.2.2 Global Pidotimod Revenue by Application (2025-2030)
5.2.3 Global Pidotimod Revenue Market Share by Application (2019-2030)
5.3 Global Pidotimod Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Active Peptide Company
6.1.1 Active Peptide Company Corporation Information
6.1.2 Active Peptide Company Description and Business Overview
6.1.3 Active Peptide Company Pidotimod Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Active Peptide Company Pidotimod Product Portfolio
6.1.5 Active Peptide Company Recent Developments/Updates
6.2 Reco Tech
6.2.1 Reco Tech Corporation Information
6.2.2 Reco Tech Description and Business Overview
6.2.3 Reco Tech Pidotimod Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Reco Tech Pidotimod Product Portfolio
6.2.5 Reco Tech Recent Developments/Updates
6.3 Manus Aktteva Biopharma
6.3.1 Manus Aktteva Biopharma Corporation Information
6.3.2 Manus Aktteva Biopharma Description and Business Overview
6.3.3 Manus Aktteva Biopharma Pidotimod Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Manus Aktteva Biopharma Pidotimod Product Portfolio
6.3.5 Manus Aktteva Biopharma Recent Developments/Updates
6.4 Joyochem
6.4.1 Joyochem Corporation Information
6.4.2 Joyochem Description and Business Overview
6.4.3 Joyochem Pidotimod Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Joyochem Pidotimod Product Portfolio
6.4.5 Joyochem Recent Developments/Updates
6.5 Changzhou Yinsheng Pharmaceutical
6.5.1 Changzhou Yinsheng Pharmaceutical Corporation Information
6.5.2 Changzhou Yinsheng Pharmaceutical Description and Business Overview
6.5.3 Changzhou Yinsheng Pharmaceutical Pidotimod Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Changzhou Yinsheng Pharmaceutical Pidotimod Product Portfolio
6.5.5 Changzhou Yinsheng Pharmaceutical Recent Developments/Updates
6.6 Dr. Reddy’s
6.6.1 Dr. Reddy’s Corporation Information
6.6.2 Dr. Reddy’s Description and Business Overview
6.6.3 Dr. Reddy’s Pidotimod Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr. Reddy’s Pidotimod Product Portfolio
6.6.5 Dr. Reddy’s Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pidotimod Industry Chain Analysis
7.2 Pidotimod Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pidotimod Production Mode & Process
7.4 Pidotimod Sales and Marketing
7.4.1 Pidotimod Sales Channels
7.4.2 Pidotimod Distributors
7.5 Pidotimod Customers
8 Pidotimod Market Dynamics
8.1 Pidotimod Industry Trends
8.2 Pidotimod Market Drivers
8.3 Pidotimod Market Challenges
8.4 Pidotimod Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
